Dr. Sirajeddin Belkhair, MD, MHSc, FRCSC
Dr. Sirajeddin Belkhair is the chairman of Neurosurgery Department and Director of Neurosurgery Residency Program at Hamad Medical Corporation (HMC) since January 2019. He is also the Chairman of the Qatari National Advisory Committee for Neurological Tumors since September 2019. Dr. Sirajeddin joined Hamad Medical Corporation in July 2018 as a senior consultant at the Department of Neurosurgery. Prior to that, he practiced in United States of America (USA) as an assistant professor in Neurosurgery Department at Saint Louis University Hospital in Missouri and at hospitals affiliated with Michigan state University in Michigan, Dr. Sirajeddin completed his neurosurgery residency training at Dalhousie University in Halifax, Canada. In addition to that, he completed two clinical fellowships from University of Toronto, Canada, first one was in open cerebrovascular neurosurgery and second fellowship was in complex spine surgery, this high-quality training in North America enabled him to perform complex cerebrovascular surgeries, spine surgeries and advance the neurosurgical treatment provided to patients of Hamad Medical Corporation.
Dr. Sirajeddin also obtained a master’s degree in Clinical Epidemiology from University of British Columbia in Vancouver, Canada.
Dr. Sirajeddin Belkhair published more than 30 publications in peer review journals and textbooks, Dr. Sirajeddin has an essential role in advancing research at neurosurgery department at HMC and he is the primary author in multiple research projects including randomized control trail that is currently being conducted by him and his team.
